Making sense of big data in health research: Towards an EU action plan
Abstract
Medicine and healthcare are undergoing profound changes. Whole-genome sequencing and high-resolution imaging technologies are key drivers of this rapid and crucial transformation. Technological innovation combined with automation and miniaturization has triggered an explosion in data production that will soon reach exabyte proportions. How are we going to deal with this exponential increase in data production? The potential of "big data" for improving health is enormous but, at the same time, we face a wide range of challenges to overcome urgently. Europe is very proud of its cultural diversity; however, exploitation of the data made available through advances in genomic medicine, imaging, and a wide range of mobile health applications or connected devices is hampered by numerous historical, technical, legal, and political barriers. European health systems and databases are diverse and fragmented. There is a lack of harmonization of data formats, processing, analysis, and data transfer, which leads to incompatibilities and lost opportunities. Legal frameworks for data sharing are evolving. Clinicians, researchers, and citizens need improved methods, tools, and training to generate, analyze, and query data effectively. Addressing these barriers will contribute to creating the European Single Market for health, which will improve health arid healthcare for all Europearis. ; Funding Agencies|European Union [115568, 603160, 282510, 664691, 115749, 305033, 305397, 288028, 242189, 211601]; European Molecular Biology Laboratory; Wellcome Trust [WT098051]; [115372]; [257082]; [291814]; [291728]; [321567]; [262055]; [115446]; [602552]; [644753]; [634143]; [261357]; [305280]; [115525]; [2011 23 02]; [270089]; [278433]; [602525]; [201418]; [242135]; [260558]; [223411]; [305626]; [115621]; [611388]; [306000]; [354457]; [305564]; [115010]; [269978]
Themen
Sprachen
Englisch
Verlag
Linköpings universitet, Avdelningen för kliniska vetenskaper; Linköpings universitet, Medicinska fakulteten; Region Östergötland, Allergicentrum US; European Institute Syst Biol and Med, France; University of Lyon, France; University of Luxembourg, Luxembourg; Wellcome Trust Sanger Institute, England; Semmelweis University, Hungary; Pfizer Inc, MA 02139 USA; IACS IIS Aragon, Spain; EL IXIR, England; Austrian Academic Science, Austria; Medical University of Vienna, Austria; Max Planck Institute Informat, Germany; Principe Felipe Research Centre, Spain; University of Florida, FL 32610 USA; Bluecompan Ltd, England; KPMG Luxembourg, Luxembourg; Leiden University, Netherlands; European Org Nucl Research CERN, Switzerland; University of Utrecht, Netherlands; European Bioinformat Institute EMBL EBI, England; University of Saarland, Germany; Forschungszentrum Julich, Germany; University of London Imperial Coll Science Technology and Med, England; BIST, Spain; TU Wien, Austria; Assoc British Pharmaceut Ind, England; University of Klinikum Aachen, Germany; SYNAPSE Research Management Partners, Spain; University of Sheffield, England; University of Leeds, England; Kings Coll London, England; Genom England, England; University of Athens, Greece; Vitr Healthcare Holding BV, Netherlands; Fraunhofer Institute Molecular Biol and Appl Ecol ScreeningPor, Germany; ITTM SA, Luxembourg; Pfizer Ltd, England; Max Planck Institute for Informatics, Saarbrucken, Germany; Health Econ and Outcomes Research, Belgium; Janssen Pharmaceut NV, Belgium; University of Manchester, England; Institute Curie, France; Linguamat Ltd, England; PwC Luxembourg, Luxembourg; Philips, Netherlands; KU Leuven Kulak, Belgium; University of Valencia, Spain; SIB, Switzerland; University of Basel, Switzerland; Agency Health Qual and Assessment Catalonia AQuAS, Spain; EuroBioForum Fdn, Netherlands; Integrated BioBank Luxembourg, Luxembourg; Technopolis Grp, England; Hospital Clin Barcelona, Spain; European Platform Patients Org Science and Ind Epposi, Belgium; CRS4, Italy; BBMRI ERIC, Austria; BIOMED CENTRAL LTD
DOI
Problem melden